Все публикации

0:00:39

Register to Attend ASCO #GU25 Today

0:00:36

ASCO Voices at 2025 ASCO Annual Meeting

0:00:33

ASCO GI Symposium - reasons to attend

0:00:24

Why Submit to ASCO #GI25? Hear From the Experts

0:00:37

Hear From Your Peers on Why You Should Submit to ASCO #GU25

0:00:54

Register Today and Meet the People Behind the Research at ASCO #GI25

0:49:19

2025 Physician Fee Schedule Proposed Rule and the Impact on Oncology

0:00:36

Hear From the Experts on Why You Should Attend #ASCOQTLY24

0:04:46

First-Line Nivolumab/Ipilimumab Improves Survival in Unresectable Hepatocellular Carcinoma

0:07:52

Nivo+Gem/Cis Is Durable, Improves Survival in Patients With Lymph Node–Only mUC

0:06:00

Osimertinib Improves PFS in EGFR-Mutant, Unresectable, Stage III NSCLC

0:05:08

Consolidation Durvalumab Could Be New SOC in Limited-Stage SCLC

0:04:11

CROSS Inferior to FLOT in Patients With Esophageal Adenocarcinoma

0:05:52

Telehealth Equally Effective as In-Person Palliative Care in Maintaining QOL in Advanced Lung Cancer

0:06:43

Neoadjuvant Nivolumab + Ipilimumab Could Be New SOC in Stage III Melanoma

0:03:32

Adagrasib Improves PFS in Patients With KRASG12C-Mutated NSCLC

0:04:55

Amivantamab + Lazertinib Administration Method May Affect Outcomes in Advanced NSCLC

0:00:44

What Makes #ASCOQTLY24 a Must-Attend Meeting

0:00:46

Global Volunteer Month 2024

0:00:57

Dr. Angela DeMichele on Why You Should Attend Our Flagship Best of ASCO Meeting

0:00:37

#ASCOBT24: Bringing International Colleagues to the APAC Region

0:00:28

#ASCOBT24: Explore What We Have Planned for You

0:01:49

Dr. Melvin Chua Invites You to Register for #ASCOBT24

0:00:48

Hear From Past Attendees on Why You Can't Miss #ASCOBT24